Merck’s Vorapaxar Overcomes Trial Questions, Committee Recommends Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee says that TRA2P trial’s interim analysis issues did not affect interpretation of its results.